Advertisement
Screener

ASTRAZENECA PLC (AZN) Form 6-K: Report of foreign private issuer

2.4 / 5 stars · 19/40 Roast Me

Add as a preferred source on Google

ASTRAZENECA PLC Form 6-K: Report of foreign private issuer

Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.

  • 2026-09-23: Form 6-K; Period of report 2026-09-23; Description TRIXEO APPROVED IN EU FOR ASTHMA; Document a8652v.htm.
  • 2026-09-21: Form 6-K; Period of report 2026-09-21; Description KLYGEFA RECOMMENDED FOR EU APPROVAL BY CHMP; Document a4455v.htm.
  • 2026-09-21: Form 6-K; Period of report 2026-09-21; Description ENHERTU RECOMMENDED FOR APPROVAL IN EU IN EARLY BC; Document a4447v.htm.
  • 2026-09-18: Form 6-K; Period of report 2026-09-18; Description DIRECTOR/PDMR SHAREHOLDING; Document a2662v.htm.
FiledFormPeriod of reportDescriptionDocument
2026-09-236-K2026-09-23TRIXEO APPROVED IN EU FOR ASTHMAa8652v.htm
2026-09-216-K2026-09-21KLYGEFA RECOMMENDED FOR EU APPROVAL BY CHMPa4455v.htm
2026-09-216-K2026-09-21ENHERTU RECOMMENDED FOR APPROVAL IN EU IN EARLY BCa4447v.htm
2026-09-186-K2026-09-18DIRECTOR/PDMR SHAREHOLDINGa2662v.htm
2026-09-156-K2026-09-15DIRECTOR/PDMR SHAREHOLDINGa8240u.htm
2026-09-156-K2026-09-15DIRECTOR/PDMR SHAREHOLDINGa8243u.htm
2026-09-146-K2026-09-14UPDATE ON SERENA-4 PHASE III TRIALa5238u.htm
2026-09-086-K2026-09-08IMFINZI+IMDELLTRA IMPROVED OS IN SMALL CELL LUNGa8764t.htm
2026-09-086-K2026-09-08ETCAMAH APPROVED IN THE US FOR HR+ BREAST CANCERa5662t.htm
2026-09-016-K2026-09-01ADMISSION OF FURTHER SECURITIES TO TRADINGa7700s.htm
2026-09-016-K2026-09-01TOTAL VOTING RIGHTSa7697s.htm
2026-09-016-K2026-09-01ADMISSION TO TRADING - EUR2.55 BILLION BOND OFFERINGa6788s.htm
2026-09-016-K2026-09-01ENHERTU APPROVED IN EU FOR 1L HER2-POSITIVE MBCa7351s.htm
2026-09-016-K2026-09-01DIRECTORATE CHANGEa7296s.htm
2026-09-016-K2026-09-01ASTRAZENECA COMPLETES AGREEMENT FOR ZEGFROVYa7349s.htm
2026-09-016-K2026-09-01TAGRISSO + ORPATHYS IMPROVED PFS IN 1L EGFRM LUNGa7347s.htm
2026-08-276-K2026-08-27TEZSPIRE CROSSING TRIAL MET PRIMARY ENDPOINTSa4036s.htm
2026-08-256-K2026-08-25ASTRAZENECA PRICES A EUR2.55 BILLION BOND OFFERINGa9590r.htm
2026-08-196-K2026-08-19DIRECTOR/PDMR SHAREHOLDINGa3225r.htm
2026-08-176-K2026-08-17ENHERTU IMPROVED PFS IN 1L HER2M LUNG CANCERa8443q.htm
2026-08-176-K2026-08-17UPDATE ON EVOLVE-LUNG02 PHASE III TRIALa8439q.htm
2026-08-176-K2026-08-17TAGRISSO+ORPATHYS IMPROVED PFS & OS IN EGFRM LUNGa8441q.htm
2026-08-036-K2026-08-03ADMISSION OF FURTHER SECURITIES TO TRADINGa8757o.htm
2026-08-036-K2026-08-03TOTAL VOTING RIGHTSa8728o.htm
2026-07-316-K2026-07-31DATROWAY APPROVED IN EU FOR TNBCa7288o.htm
2026-07-276-K2026-07-27UPDATE ON ULTOMIRIS PHASE III TRIAL IN HSCT-TMAa8707n.htm
2026-07-276-K2026-07-27SONE-VE IMPROVED SURVIVAL IN GASTRIC CANCERSa9459n.htm
2026-07-276-K2026-06-30FORM 6-Kazn-20260630x6k.htm
2026-07-236-K2026-07-23ETCAMAH APPROVED IN THE EU FOR ER+ BREAST CANCERa5622n.htm
2026-07-146-K2026-07-14ASTRAZENECA LICENSES NOVEL EGFR INHIBITORa2449m.htm
2026-07-096-K2026-07-09UPDATE ON CARDIO-TTRANSFORM PHASE III TRIALa6054l.htm
2026-07-016-K2026-07-01ADMISSION OF FURTHER SECURITIES TO TRADINGa6348k.htm
2026-07-016-K2026-07-01TOTAL VOTING RIGHTSa6365k.htm
2026-06-296-K2026-06-29ENHERTU APPROVED IN EU FOR HER2+ SOLID TUMOURSa1370k.htm
2026-06-296-K2026-06-29DATROWAY RECOMMENDED FOR APPROVAL IN EU FOR TNBCa0148k.htm
2026-06-156-K2026-06-15TRUQAP APPROVED IN US FOR PROSTATE CANCERa1987i.htm
2026-06-016-K2026-06-01ADMISSION OF FURTHER SECURITIES TO TRADINGa4701g.htm
2026-06-016-K2026-06-01TOTAL VOTING RIGHTSa4717g.htm
2026-05-296-K2026-05-29IMFINZI APPROVED IN US FOR EARLY BLADDER CANCERa1377g.htm
2026-05-276-K2026-05-27US FDA DECISION DATE ON CAMIZESTRANT EXTENDEDa7798f.htm
2026-05-266-K2026-05-26DATROWAY APPROVED IN US FOR 1L TRIPLE-NEGATIVE BCa6573f.htm
2026-05-266-K2026-05-26ENHERTU RECOMMENDED IN EU FOR HER2+ SOLID TUMOURSa6571f.htm
2026-05-266-K2026-05-26CAMIZESTRANT RECOMMENDED FOR BREAST CANCER IN EUa6568f.htm
2026-05-186-K2026-05-18DIRECTOR/PDMR SHAREHOLDINGa7391e.htm
2026-05-186-K2026-05-18BAXFENDY APPROVED IN THE US FOR HYPERTENSIONa6161e.htm
2026-05-186-K2026-05-18ENHERTU APPROVED IN TWO HER2+ EARLY BC SETTINGSa6159e.htm
2026-05-146-K2026-05-14IMFINZI + EV IMPROVES EFS & OS IN BLADDER CANCERa3223e.htm
2026-05-016-K2026-05-01TOTAL VOTING RIGHTS AND ADMISSION OF SHARESa8007c.htm
2026-05-016-K2026-05-01FDA ODAC VOTE ON CAMIZESTRANT IN BREAST CANCERa7028c.htm
2026-05-016-K2026-05-01FDA ODAC RECOMMENDS TRUQAP IN PROSTATE CANCERa7026c.htm
2026-04-296-K2026-04-291ST QUARTER RESULTSa2999c.htm
2026-04-286-K2026-04-28BREZTRI APPROVED IN THE US FOR ASTHMAa1866c.htm
2026-04-276-K2026-04-27SAPHNELO SELF-ADMINISTRATION APPROVED IN THE USa9587b.htm
2026-04-236-K2026-04-23DIRECTORATE CHANGEa5427b.htm
2026-04-216-K2026-04-21I CAN PHIII INTERIM ANALYSIS MET PRIMARY ENDPOINTa2016b.htm
2026-04-206-K2026-04-20THIRD TOZORAKIMAB POSITIVE PHASE III IN COPDa0190b.htm
2026-04-096-K2026-04-09RESULT OF AGMa8862z.htm
2026-04-026-K2026-04-02IMFINZI+IMJUDO IMPROVES PFS IN EARLY LIVER CANCERa2331z.htm
2026-04-016-K2026-04-01TOTAL VOTING RIGHTS AND ADMISSION OF SHARESa9429y.htm
2026-03-316-K2026-03-31EFZIMFOTASE ALFA PH3 PROGRAM SHOW POSITIVE RESULTSa7230y.htm
2026-03-276-K2026-03-27TOZORAKIMAB MET OBERON/TITANIA PRIMARY ENDPOINTSa4270y.htm
2026-03-206-K2026-03-20NOTIFICATION OF ADMISSION OF SHARESa3904x.htm
2026-03-166-K2026-03-16IMFINZI APPROVED IN EU FOR EARLY GASTRIC CANCERa7541w.htm
2026-03-106-K2026-03-10NOTICE OF AGMa0663w.htm
2026-03-106-K2026-03-10FORM 6-Ktm268365d1_6k.htm
2026-03-066-K2026-03-06DIRECTOR/PDMR SHAREHOLDINGa6803v.htm
2026-03-066-K2026-03-06DIRECTOR/PDMR SHAREHOLDINGa6797v.htm
2026-03-066-K2026-03-06DIRECTOR/PDMR SHAREHOLDINGa6795v.htm
2026-03-026-K2026-03-02TOTAL VOTING RIGHTSa7886u.htm
2026-03-026-K2026-03-02FORM 6-Ktm267648d3_6k.htm
2026-02-266-K2026-02-26ASTRAZENECA PRICES A $2BN BOND OFFERINGa4537u.htm
2026-02-256-K2026-02-25FILING OF FORM 20-F WITH SECa0829u.htm
2026-02-246-K2026-02-24ANNUAL FINANCIAL REPORTa0823u.htm
2026-02-246-K2026-02-24DIRECTORATE CHANGEa0817u.htm
2026-02-246-K2026-02-24FORM 6-Ktm261135d3_6k.htm
2026-02-206-K2026-02-20FIXED-DURATION CALQUENCE COMBO APPROVED IN USa7832t.htm
2026-02-106-K2026-02-10FINAL RESULTSa3234s.htm
2026-02-036-K2026-02-03UPDATE ON SAPHNELO SUBCUTANEOUS ADMINISTRATIONa4833r.htm
2026-02-026-K2026-02-02TOTAL VOTING RIGHTSa1980r.htm
2026-02-026-K2026-02-02IMFINZI RECOMMENDED IN EU FOR EARLY GASTRIC CANCERa2764r.htm
2026-02-026-K2026-02-02ASTRAZENECA BEGINS TRADING ON NYSEa2714r.htm
2026-01-306-K2026-01-30ASTRAZENECA AGREES OBESITY AND T2D DEAL WITH CSPCa0031r.htm
2026-01-296-K2026-01-29ASTRAZENECA INVESTS $15BN IN CHINA THROUGH 2030a9169q.htm
2026-01-206-K2026-01-20ASTRAZENECA TO COMPLETE DIRECT LISTING ON NYSEa4875p.htm
2026-01-086-K2026-01-08AZN NEW HEAD OF INVESTOR RELATIONS JORIS SILONa0621oastra.htm
2026-01-026-K2026-01-02TOTAL VOTING RIGHTSa4560n.htm
Advertisement